Compare Amgen, Inc. (AMGN) vs NetEase Inc (NTES) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs NetEase Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while NetEase Inc trades at $131.66 (market cap $84.43B). The key difference: Amgen, Inc. is far larger — about 2.3× NetEase Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | NTES | |
|---|---|---|
Market Cap | $196.12B | $84.43B |
Sector | Health | Media |
52-Week High | $388.16 | $159.34 |
52-Week Low | $271.18 | $109.26 |
Enterprise Value | $241.41B | $60.90B |
Dividend Yield | 2.77% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
NetEase (NTES) trades at $128.03, down 4.39% today, with strong fundamentals including 29.84% net income margin and $33.76B net income for 2025. The stock shows bullish technical signals with moving averages supporting upside, while RSI indicates potential overbought conditions. Recent Q1 2026 earnings beat expectations with $2.53 EPS versus $2.19 expected, demonstrating continued operational strength.
Wall Street maintains strong bullish sentiment with 82% buy ratings and 34.7% upside potential to analyst targets. Key risks include China market exposure and competitive gaming industry dynamics, but the company's $137.58B cash position and expanding international revenue provide solid foundation for growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
